Cargando…
Dual block HER2 assessment increased HER2 immunohistochemistry positive rate in resected specimens of gastric cancer: a prospective multicenter clinical trial from China
BACKGROUND: Former single center studies indicated that HER2 assessment with two primary tumor blocks (dual block HER2 assessment) could be an efficient and practical approach to overcome the adverse impact of heterogeneity and acquire a HER2 positive rate in gastric cancer (GC). This multicenter pr...
Autores principales: | Xu, Chen, Sun, Miaomiao, Jin, Mei, Li, Zengshan, Qin, Rong, Ren, Guoping, Sun, Wenyong, Chen, Lirong, Luan, Lijuan, Liu, Yalan, Jiang, Dongxian, Chen, Lingli, Luo, Rongkui, Hou, Yingyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238183/ https://www.ncbi.nlm.nih.gov/pubmed/35765007 http://dx.doi.org/10.1186/s13000-022-01230-7 |
Ejemplares similares
-
Tumor containing fragment number influences immunohistochemistry positive rate of HER2 in biopsy specimens of gastric cancer
por: Xu, Chen, et al.
Publicado: (2017) -
HER2 Positivity Is Affected by the Papillary Structure and Has a Bidirectional Prognostic Value for Gallbladder Carcinoma
por: Chen, Lingli, et al.
Publicado: (2022) -
HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens
por: Nishimura, Rieko, et al.
Publicado: (2016) -
Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
por: Chen, Hai-long, et al.
Publicado: (2021) -
Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatment
por: Xu, Chen, et al.
Publicado: (2019)